hiv disease
Recently Published Documents


TOTAL DOCUMENTS

2347
(FIVE YEARS 225)

H-INDEX

86
(FIVE YEARS 6)

Author(s):  
Cunningham-Rundles Susanna ◽  
Lenora M. Noroski ◽  
Joseph S. Cervia
Keyword(s):  

2022 ◽  
Vol 2022 ◽  
pp. 1-14
Author(s):  
Farouk F. Abou Hassan ◽  
Mirna Bou Hamdan ◽  
Khalil El Asmar ◽  
Nada M. Melhem

Combined antiretroviral therapy (cART) increased the life expectancy of people living with HIV (PLHIV) and remarkably reduced the morbidity and mortality associated with HIV infection. However, non-AIDS associated comorbidities including diabetes, hypertension, hyperlipidemia, and cardiovascular diseases (CVD) are increasingly reported among PLHIV receiving cART. Killer cell immunoglobulin receptors (KIRs) expressed on the surface of natural killer (NK) cells have been previously implicated in controlling HIV disease progression. The aim of this study is to investigate the role of KIRs in developing non-AIDS associated comorbidities among PLHIV. Demographic and behavioral data were collected from voluntary participants using a standardized questionnaire. Whole blood samples were collected for KIR genotyping. Hypertension (29.5%) and hyperlipidemia (29.5%) followed by diabetes (23.7%) and CVD (9.7%) were mainly reported among our study participants with higher rate of comorbid conditions observed among participants > 40 years old. The observed KIR frequency (OF) was ≥90% for inhibitory KIR2DL1 and KIR3DL1, activating KIR2DS4 and the pseudogene KIR2DP1 among study participants. We detected significant differences in the expression of KIR3DS4 and KIR3DL1 ( p = 0.038 ) between diabetic and nondiabetic and in the expression of KIR2DL3 between hypertensive and normotensive HIV-infected individuals ( p = 0.047 ). Moreover, KIR2DL1 and KIR2DP1 were associated with significantly reduced odds of having CVD (OR 0.08; 95% CI: 0.01-0.69; p = 0.022 ). Our study suggests the potential role of KIR in predisposition to non-AIDS comorbidities among PLHIV and underscores the need for more studies to further elucidate the role of KIRs in this population.


Author(s):  
Jennifer L. Thompson ◽  
Steven Paul Woods ◽  
Luis D. Medina ◽  
Troy A. Webber

Author(s):  
Sandile Cele ◽  
Farina Karim ◽  
Gila Lustig ◽  
James Emmanuel San ◽  
Tandile Hermanus ◽  
...  

2021 ◽  
Vol 8 (1) ◽  
pp. 16
Author(s):  
Mathieu Nacher ◽  
Kinan Drak Alsibai ◽  
Loïc Epelboin ◽  
Philippe Abboud ◽  
Frédégonde About ◽  
...  

Disseminated histoplasmosis is a common differential diagnosis of tuberculosis in disease-endemic areas. We aimed to find a predictive score to orient clinicians towards disseminated histoplasmosis or tuberculosis when facing a non-specific infectious syndrome in patients with advanced HIV disease. We reanalyzed data from a retrospective study in Cayenne Hospital between January 1997–December 2008 comparing disseminated histoplasmosis and tuberculosis: 100 confirmed disseminated histoplasmosis cases and 88 confirmed tuberculosis cases were included. A simple logit regression model was constructed to predict whether a case was tuberculosis or disseminated histoplasmosis. From this model, a score may be obtained, where the natural logarithm of the probability of disseminated histoplasmosis/tuberculosis = +3.917962 × WHO performance score (1 if >2, 0 if ≤2) −1.624642 × Pulmonary presentation (1 yes, 0 no) +2.245819 × Adenopathies > 2 cm (1 yes, 0 no) −0.015898 × CD4 count − 0.001851 × ASAT − 0.000871 × Neutrophil count − 0.000018 × Platelet count + 6.053793. The area under the curve was 98.55%. The sensitivity of the model to distinguish between disseminated histoplasmosis and tuberculosis was 95% (95% CI = 88.7–98.3%), and the specificity was 93% (95% CI = 85.7.3–97.4%). In conclusion, we here present a clinical-biological predictive score, using simple variables available on admission, that seemed to perform very well to discriminate disseminated histoplasmosis from tuberculosis in French Guiana in well characterized patients.


2021 ◽  
Author(s):  
Kelli Sullivan ◽  
Matthew Gallagher ◽  
Romola S. Bucks ◽  
Michael Weinborn ◽  
Steven Paul Woods

Objective: The Memory for Intentions Test (MIsT) is a clinical measure of prospective memory that has strong evidence for convergent, discriminative, and ecological validity. This study evaluates the latent structure of the MIsT among two samples who may experience prospective memory deficits: older adults and people living with HIV disease. Participants and Methods: Study participants included 303 people with HIV disease (ages 18-67) and 267 community-dwelling older adults (ages 50-91). Confirmatory factor analyses of the MIsT were conducted separately in each sample. We evaluated a one-factor model, as well as three two-factor models with the MIsT items loading onto each factor based on cue type, delay interval, or response modality, respectively. Results: The one-factor model provided the best (and most parsimonious) fit to the data in both study samples. All two-factor models also demonstrated good fit statistics, although correlations between the two factors in each model were high and none of the two-factor models provided a significantly better fit than the one-factor model. Conclusions: Results provide support for the factor structure of the MIsT in older adults and people with HIV disease. A total score for the MIsT provides the most parsimonious solution, although available evidence and theory also support the use of subscales (e.g., cue type). Future studies of the MIsT would be useful to determine its psychometrics in different clinical populations.


2021 ◽  
Vol 10 (2) ◽  
pp. 62
Author(s):  
Ninuk Dian Kurniawati ◽  
Adi Sukma Septiana ◽  
Muhammad Iqbal ◽  
Laely Sholihah ◽  
Dyah Sekaringtyas Ciptaningrum ◽  
...  

Introduction: Inadequate nutritional status in a person with HIV-AIDS (PLWHA) has a high risk of declining health in general. If a person is infected with HIV but has a good nutritional status, his immune system will be better than someone who is infected with HIV but has poor nutritional status. With good nutritional status, it can prevent HIV disease from entering the AIDS stage. Malnutrition that occurs in a person with HIV/AIDS can accelerate the progression of HIV disease and hinder treatment, thereby worsening the patient's condition. The use of Antiretroviral (ARV) has an effect that can worsen a person's condition if it is not accompanied by good nutritional intake.Methods: The method used in this study is a literature review with predetermined inclusion and exclusion criteria. Sample: The total number of samples obtained from the results of the literature review is 128 respondents. The instrument used in evaluating the research is using an instrument from The Joanna Briggs Institute (JBI). Results: Protein-energy enriched macronutrient supplementation along with ARV initiation was effective in improving physiological nutritional status and immune response in PLWHA.Conclusion: This can prevent people living with HIV from experiencing malnutrition and wasting, can restore the ideal body weight, increase and maintain the body's ability to fight various opportunistic infections, increase the effect of drugs, and can improve and improve the quality of life of PLWHA patients


PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0260251
Author(s):  
Michael D. Virata ◽  
Sheela V. Shenoi ◽  
Joseph Ladines-Lim ◽  
Merceditas S. Villanueva ◽  
Lydia A. Barakat

There continue to be conflicting data regarding the outcomes of people with HIV (PWH) who have COVID-19 infection with most studies describing the early epidemic. We present a single site experience spanning a later timeframe from the first report on January 21, 2020 to January 20, 2021 and describe clinical outcomes and predictors of hospitalization among a cohort of PWH in an urban center in Connecticut, USA. Among 103 PWH with controlled HIV disease, hospitalization occurred in 33% and overall mortality was 1%. HIV associated factors (CD4 count, HIV viral suppression) were not associated with hospitalization. Chronic lung disease (OR: 3.35, 95% CI:1.28–8.72), and cardiovascular disease (OR: 3.4, 95% CI:1.27–9.12) were independently associated with hospitalization. An increasing number of non-communicable comorbidities increased the likelihood of hospitalization (OR: 1.61, 95% CI:1.22–2.13).


2021 ◽  
Author(s):  
Nyuma Mbewe ◽  
Michael J. Vinikoor ◽  
Sombo Fwoloshi ◽  
Mundia Mwitumwa ◽  
Shabir Lakhi ◽  
...  

Abstract Background Zambia recently achieved UNAIDS 90-90-90 treatment targets for HIV epidemic control; however, inpatient facilities continue to face a large burden of patients with advanced HIV disease and HIV-related mortality. Management of advanced HIV disease, following guidelines from outpatient settings, may be more difficult within complex inpatient settings. We evaluated adherence to HIV guidelines during hospitalization, including opportunistic infection (OI) screening, treatment, and prophylaxis. Methods We reviewed inpatient medical records of people living with HIV (PLHIV) admitted to the University Teaching Hospital in Lusaka, Zambia between December 1, 20218 and April 30, 2019. We collected data on patient demographics, antiretroviral therapy (ART), HIV biomarkers, and OI screening and treatment – including tuberculosis (TB), Cryptococcus, and OI prophylaxis with cotrimoxazole (CTX). Screening and treatment cascades were constructed based on the 2017 WHO Advanced HIV Guidelines. Results We reviewed files from 200 charts of patients with advanced HIV disease; of these 92% (184/200) had been on ART previously; 58.1% (107/184) for more than 12 months. HIV viral load (VL) testing was uncommon but half of VL results were high. 39% (77/200) of patients had a documented CD4 count result. Of the 172 patients not on anti-TB treatment (ATT) on admission, TB diagnostic tests (either sputum Xpert MTB/RIF MTB/RIF or urine TB-LAM) were requested for 105 (61%) and resulted for 60 of the 105 (57%). Nine of the 14 patients (64%) with a positive lab result for TB died before results were available. Testing for Cryptococcosis was performed predominantly in patients with symptoms of meningitis. Urine TB-LAM testing was rarely performed. Conclusions Inconsistent CD4 testing reduced recognition of advanced HIV and OI screening was suboptimal, in part due to laboratory challenges. HIV programs can potentially reduce mortality and identify PLHIV with retention and adherence issues through strengthening inpatient activities, including VL testing.


Sign in / Sign up

Export Citation Format

Share Document